To conclude, our work demonstrated the anti-cancer activity of HZ-A-018 in gastric cancer, and demonstrated the synergistic effects of combination treatment with HZ-A-018 and 5-FU through the inhibition of RRM2 via AKT/S6 suppression, thereby providing a novel therapeutic strategy in gastric cancer. Here, RPS6 is linked to cancer.